DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023" report to their offering.
Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 report gives comprehensive insight on various clinical and non-clinical advancements in the global dendritic cell cancer vaccine market.
In recent years, dendritic cell cancer vaccines have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 53 dendritic cell cancer vaccines in clinical pipeline. Most of the dendritic cell cancer vaccines are in preclinical phase followed by phase-II clinical trials.
Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023 Highlights:
- Global Dendritic Cell Cancer Vaccine Market Overview
- Assessment of Dendritic Vaccines with Other Therapeutic Regimens
- Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase
- Marketed Dendritic Cell Vaccines Clinical Insight
- Dendritic Cells Mechanizing Immune Response
- Future Growth Opportunities
Key Topics Covered:
1. Advent of Dendritic Vaccine in Oncology
2. Cataloging towards Dendritic Cells
3. Dendritic Cells Mechanizing Immune Response
3.1 Antigen Appearance Leads to Cellular Immune Responses
3.2 Stacking of Distinct Antigens over Dendritic Cells
3.3 Dendritic Cells Source & Subsets
3.4 Trail towards Maturation
3.5 Stimulation Initiates Maturation
3.6 Migration to Lymph Node
3.7 Precision of Dendritic Cells Vaccination
3.8 Illustrations of Clinical Results among Varied Cancer
3.9 Quality Control
3.10 Immune Monitoring
4. Equipping Dendritic Cell Vaccines
4.1 Cross Presentation of CD4 T-CD8 T Cells
4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
4.3 Strategies to Activate NKT Cells
5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens
5.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
5.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
5.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
5.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine
6. Dendritic Cell Cancer Vaccine Market & Clinical Insight
6.1 Some Trends Involving Dendritic Cells Cancer Vaccination
6.2 Dendritic Cell Cancer Vaccine Pipeline Overview
7. Undercurrents of Dendritic Cancer Vaccine Growth
8. Challenging Milieu for Dendritic Cancer Vaccine
9. Prospective Trajectories for Future
10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Clinical
10.4 Phase I
10.5 Phase I/II
10.6 Phase II
10.7 Phase II/III
10.8 Phase III
11. Marketed Dendritic Cell Vaccines Clinical Insight
11.1 Sipuleucel-T (Provenge)
11.2 Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC & CreaVax-RCC)
11.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
12. Competitve Landscape
- 3M Company
- Activartis
- Argos Therapeutics
- Batavia Bioservices
- Bellicum Pharmaceuticals
- Creagene
- DanDrit Biotech
- DCPrime
- Dendreon Corporation
- Elios Therapeutics
- Glaxo Smith Kline
- Immunicum
- ImmunoCellular Therapeutics
- Kiromic
- Medigene
- Merck
- Northwest Biotherapeutics
- SOTIO
- Tella Incorporation
- Theravectys
- Vaxil BioTherapeutics
For more information about this report visit http://www.researchandmarkets.com/research/t37crd/global_dendritic
